More MS news articles for Mar 2002

Mycophenolate mofetil in the therapy of polymyositis associated with a polyautoimmune syndrome

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=11870700&dopt=Abstract

Muscle Nerve 2002 Feb;25(2):286-8
Schneider C, Gold R, Schafers M, Toyka KV.
Department of Neurology and Clinical Research Group for Multiple Sclerosis and Neuroimmunology, University of Wurzburg, Josef-Schneider-Str. 11, 97080 Wurzburg, Germany.

Mycophenolate mofetil 1.5 g daily (30 mg/kg body weight) was given to a patient with ankylosing spondylitis, ulcerative colitis, and severe refractory polymyositis after conventional treatment regimes had failed.

No severe side effects occurred.

Considerable improvement of clinical symptoms and electromyographic findings were seen within 6 months after the initiation of mycophenolate mofetil, allowing for tapering and discontinuation of methylprednisolone.

Mycophenolate mofetil may be considered as an useful alternative in the treatment of polymyositis when standard therapeutic regimens fail.

Copyright 2002 John Wiley & Sons, Inc